Thousand Oaks Biologics will participate in CPHI Milan 2026,taking place from October 6 to 8, 2026, at Fiera Milano,Italy. Visitors are invited to meet us at Booth 12F58, where it will showcase integrated CRDMO solutions supported by industrial cell culture media supply, manufacturing capability, and innovative drug discovery capabilities.
As biopharmaceutical companies seek partners that can improve R&D efficiency, manage scale-up costs, streamline technology transfer, and support regulatory compliance, Thousand Oaks Biologics provides an end-to-end development and manufacturing model spanning early-stage research, process development,clinical manufacturing, and commercialization.
JSBio, a wholly owned subsidiary of Thousand Oaks Biologics, will showcase its industrial cell culture media products and services. Its serum-free media technology enables industrialized, self-controlled production of core raw materials, while its intelligent manufacturing base supports the transition from laboratory-scale customization to commercial supply. This integrated approach is designed to strengthen supply security, improve cost efficiency, and support the industrialization of biologics manufacturing.
Thousand Oaks Biopharmaceuticals will highlight its integrated ADC CMC technology platform,which co-locates naked antibody, ADC drug substance, and ADC drug product production within a single facility. By connecting these critical stages, the platform helps streamline development, process coordination, and technology transfer for complex ADC programs. The company’s Shanghai ADC production site offers scalable manufacturing capabilities to support programs from clinical development through commercialization.
In 2026, Thousand Oaks Biopharmaceuticals successfully passed a European Qualified Person (QP) audit at its Shanghai ADC production site. This achievement marks an important milestone in the site’s commitment to EU-compliant quality standards and strengthens its readiness to support the development and commercialization of ADC products for global biopharmaceutical clients.
The company’s subsidiary, Ginspire, provides early-stage support including candidate screening, molecule design andoptimization, antibody discovery and engineering, linker-payload screening and conjugation, developability assessment, pharmacology and PK/PD studies,structural characterization, formulation development, and IND submission support. By connecting early research with downstream development and manufacturing, Ginspire creates a seamless “Early discovery to commercial manufacturing” continuum.
Through its integrated capabilities, international compliance qualifications, and global partnership strategy, Thousand Oaks Biologics is evolving from a service provider into a strategic partner for biopharmaceutical innovation.
Reference: CPHI Milan official event information
